TNFRSF8 and anaplastic large cell lymphoma: Clinical investigations have demonstrated that brentuximab vedotin attains an objective response rate of 41% in patients with CD30-positive non-invasive large cell lymphoma, excluding anaplastic large cell lymphoma (non-ALCL) subtypes (4–7).